International Stem Cell Corporation Completes Dosing Of Second Cohort In Parkinson’s Disease Clinical Trial

Recently, the International Stem Cell Corporation (ISCO) announced that its eighth participant, which completes the dosing of the second cohort of the clinical trial for Parkinson’s disease, was successfully transplanted with ISC-hpNSC® cells at the Royal Melbourne Hospital in Melbourne, Australia. ISCO’s Executive Vice President and Chief Scientific Officer Russell Kern, PhD, commented, “We are […]

Read More >>